{
    "clinical_study": {
        "@rank": "95804", 
        "arm_group": [
            {
                "arm_group_label": "Cilostazol", 
                "arm_group_type": "Active Comparator", 
                "description": "One tablet (100 mg) twice per day for 12 weeks"
            }, 
            {
                "arm_group_label": "Dummy Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "One tablet twice per day for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "1. The number and function of circulating endothelial progenitor cells (EPCs) are\n           inversely associated with coronary risk factors and atherosclerotic diseases such as\n           PAOD.\n\n        2. This double-blind, randomized, placebo-controlled trial to evaluate the effects of\n           cilostazol on human early EPCs and angiogenesis as well as the potential mechanisms of\n           action in patients with mild-to-moderate PAOD."
        }, 
        "brief_title": "Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Arterial Diseases", 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. titration of drugs\n\n             1. run-in period: eligible subjects are screened and baseline blood samples are\n                obtained\n\n             2. study period: 12 weeks\n\n                  -  24 subjects with cilostazol and 20 subjects with dummy placebo\n\n                  -  On the first day after the end of the study period, the follow-up data are\n                     obtained by the same procedure\n\n             3. blood sampling and measurement of serum biomarkers\n\n                  -  obtained from peripheral veins in all study subjects at the run-in period and\n                     the end of the treatment period of the study\n\n                  -  sent for isolation, cell culture, and assays of human EPCs\n\n                  -  also stored for enzyme-linked immunosorbent assay (Stromal cell derived\n                     factor-alfa1, adiponectin, soluble thrombomodulin, vascular endothelial\n                     growth factor)\n\n        2. assays of human EPCs\n\n             1. colony formation by EPCs\n\n             2. quantification of EPCs and apoptotic endothelial cells\n\n             3. chemotactic motility, proliferation/viability and apoptosis assays\n\n        3. collateral vessels formation and distal run-off assessed by dual-energy multi-slice\n           computed tomography angiography\n\n        4. echocardiographic examinations to evaluate left ventricular functions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ankle-brachial index (ABI) less than 0.9 in one or both legs but no obvious symptoms\n             of intermittent claudication\n\n        Exclusion Criteria:\n\n          -  obvious symptoms of intermittent claudication\n\n          -  severe PAD (Fontaine grading > 3) or critical limb ischemia in at least one leg\n\n          -  severe liver dysfunction (transaminases >10 times of upper normal limit, history of\n             liver cirrhosis, or hepatoma)\n\n          -  > stage 4 chronic kidney disease (end-stage renal disease with chronic dialysis not\n             excluded)\n\n          -  left ventricular ejection fraction <50% by echocardiography\n\n          -  documented active malignancy\n\n          -  chronic inflammatory disease\n\n          -  planned coronary intervention or endovascular therapy or bypass surgery within 3\n             months\n\n          -  known drug allergy history for cilostazol\n\n          -  current use of cilostazol or any other cAMP-elevator\n\n          -  premenopausal women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01952756", 
            "org_study_id": "NCKUH-10103043/BR-100-134"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cilostazol", 
                "Dummy Placebo"
            ], 
            "description": "one tablet twice per day for 12 weeks in both active comparator and placebo groups", 
            "intervention_name": "Active comparator (cilostazol) and Placebo comparator", 
            "intervention_type": "Drug", 
            "other_name": [
                "Active comparator: Pletaal (brand name)", 
                "Placebo comparator: Dummy placebo"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Cilostazol"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cilostazol", 
            "endothelial progenitor cells", 
            "vasculogenesis", 
            "angiogenesis", 
            "peripheral arterial disease", 
            "biomarkers"
        ], 
        "lastchanged_date": "September 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tainan", 
                    "country": "Taiwan", 
                    "zip": "704"
                }, 
                "name": "National Cheng Kung University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD", 
        "other_outcome": {
            "description": "250,000 cells are seeded in each well of a 96-well plate and the cells are added with 200 \u03bcl of the culture medium and incubated at 37\u00b0C. Medium change is performed 3 days later. On 7th day, the plate is then re-incubated with 100 \u03bcl fresh medium and additional 50 \u03bcl of 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2 Hydrogen-Tetrazolium-5-Carboxanilide reagent, and further incubated in dark at 37\u00b0C for 4 h. After incubation, the orange colored complex formed is read at 450 nm using a microplate reader with a 450 nm reference filter.", 
            "measure": "Viability (Proliferation) of EPCs", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "overall_official": {
            "affiliation": "National Cheng-Kung University Hospital", 
            "last_name": "Ting-Hsing Chao, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Peripheral blood mononuclear cells (one million cells in each) are suspended in 100 \u00b5L phosphate-buffered saline and incubated for 30 min with monoclonal antibodies against human peridinin chlorophyll protein-conjugated cluster of differentiation antigen-45, phycoerythrin-conjugated anti-human cluster of differentiation antigen-34 antibody and anti-human kinase insert domain receptor (KDR) antibody conjugated with Alexa Flour 647. Cells are washed and analyzed on a FACSCalibur flow cytometer with 100,000 events in the lymphocyte gate. EPCs, which are defined as negative for cluster of differentiation antigen-45 and positive for cluster of differentiation antigen-34 and KDR. Based on the peripheral blood mononuclear cell counts, the absolute number of circulating EPCs/\u00b5L is calculated.", 
            "measure": "Circulating EPCs Number", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "reference": [
            {
                "PMID": "22339730", 
                "citation": "Chao TH, Tseng SY, Li YH, Liu PY, Cho CL, Shi GY, Wu HL, Chen JH. A novel vasculo-angiogenic effect of cilostazol mediated by cross-talk between multiple signalling pathways including the ERK/p38 MAPK signalling transduction cascade. Clin Sci (Lond). 2012 Aug 1;123(3):147-59. doi: 10.1042/CS20110432."
            }, 
            {
                "PMID": "22473072", 
                "citation": "Biscetti F, Pecorini G, Straface G, Arena V, Stigliano E, Rutella S, Locatelli F, Angelini F, Ghirlanda G, Flex A. Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism. Int J Cardiol. 2013 Aug 10;167(3):910-6. doi: 10.1016/j.ijcard.2012.03.103. Epub 2012 Apr 2."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01952756"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Peripheral blood mononuclear cells are isolated by density gradient centrifugation according to standard protocols. After centrifugation, cells are washed, resuspended in M199 medium supplemented with 20% (vol/vol) fetal bovine serum, 10 ng/ml vascular endothelial growth factor, 2 ng/ml basic-fibroblast growth factor, 10 ng/ml epidermal growth factor and 2 ng/ml insulin growth factor, and cultured in 24-well plates coated with human fibronectin for 7 days. EPCs cells are confirmed by uptake of acetyl-low density lipoprotein and lectin and by the expression of EPC markers. Cells are harvested after 7 days, fixed and stained with crystal violet reagent. The colony densities are quantified with an Olympus microscope at 100-fold magnification using an imaging measurement software.", 
            "measure": "Colony Formation by EPCs", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "National Cheng-Kung University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Department of Health, Executive Yuan, R.O.C. (Taiwan)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Cheng-Kung University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}